Lumos Pharma (LUMO)
(Delayed Data from NSDQ)
$2.35 USD
+0.10 (4.44%)
Updated Jun 3, 2024 09:56 AM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
Lumos Pharma, Inc [LUMO]
Reports for Purchase
Showing records 61 - 77 ( 77 total )
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
2Q20 Results; LUM-201 Phase 2b Projected to Begin Before Year End
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Checklist for What SLS-002 Needs to Show Going Forward
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Takeaways from Our PGHD Expert Call with Dr. Ron Rosenfeld
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Strengthen Your PGHD Knowledge in One Hour, Today at 2PM ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Strengthen Your PGHD Knowledge in One Hour on May 19 at 2PM ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Strengthen Your PGHD Knowledge in One Hour on May 19 at 2PM ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Grow Stronger With LUM-201 in PGHD; Initiating with Buy Rating
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Lumos Pharma, Inc
Industry: Medical - Biomedical and Genetics
Strengthen Your Knowledge of PGHD in One Hour on May 19 at 2PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y